Back

Uptake of SGLT2i therapy among patients hospitalized with heart failure: Insights from the veterans affairs healthcare system

28 August 2023 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: More insights into SGLT2i in heart failure Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Anubodh Varshney

Stanford University School of Medicine, Palo Alto (United States of America)

5 More presentations in this session

Presentation thumbnail
The effect of sglt-2 inhibitor dapagliflozin on adropin serum levels in patients with chronic heart failure and concomitant type 2 diabetes mellitus
Professor A. Berezin (Salzburg, AT)
Abstract Slides Video
Presentation thumbnail
Efficacy of dapagliflozin according to geographic regions in patients with heart failure: a patient-level pooled analysis of DAPA-HF and DELIVER
Doctor T. Kondo (Nagoya, JP)
Abstract Slides Video
Presentation thumbnail
Sodium-glucose cotransporter inhibitors reduce cardiovascular outcomes regardless eGFR range in patients with heart failure. Systematic review and meta-regression meta-analysis
Doctor I. Girard Cunha Vieira Lima (Sao Paulo, BR)
Abstract Slides Video
Presentation thumbnail
Effect of sodium-related glucose transporter 2 -Inhibitors on exercise capacity in heart failure patients with reduced ejection fraction, does etiology matter?
Doctor E. Coppo (Jerez de la Frontera, ES)
Abstract Slides Video
Presentation thumbnail
Prognostic implications of angiopoietin-2 in heart failure and the influence of empagliflozin: the EMPEROR program
Professor J. Butler (Dallas, US)
Abstract Slides Video

Access the full session

Session thumbnail
More insights into SGLT2i in heart failure

The Event

Event poster

ESC Congress 2023

28 August 2023 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Description of the profile of the patient with heart failure depending on the discharge service and the possible optimization of treatment with SGLT2i in a retrospective cohort from 2021 to 2022
thumbnail
Congress Presentation
Initiation of SGLT2I during acute HF hospitalization or in the immediate period following discharge.
thumbnail
Congress Presentation
Sodium-glucose co-transporter-2 inhibitors: prognostic benefit in real-world, elderly, comorbid HFmrEF and HFpEF patients

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources